Progressive Thinning of Retinal Nerve Fiber Layer/Ganglion Cell Layer (RNFL/GCL) as Biomarker and Pharmacological Target of Diabetic Retinopathy
International Journal of Molecular Sciences · 2023
DOI: 10.3390/ijms241612672 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von Gianpaolo Zerbini und 7 weiteren Autor:innen. Beteiligte Einrichtung: Complications of Diabetes Unit, Diabetes Research Institute, IRCCS Ospedale San Raffaele, 20132 Milan, Italy. Hauptthemen laut MEDLINE: Diabetic Retinopathy, Diabetes Mellitus. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Dompé pharmaceuticals Spa, L'Aquila, Italy, Italian Ministry of Health.
Abstract (Originalsprache)
Diabetes-driven retinal neurodegeneration has recently been shown to be involved in the initial phases of diabetic retinopathy, raising the possibility of setting up a preventive strategy based on early retinal neuroprotection. To make this possible, it is crucial to identify a biomarker for early retinal neurodegeneration. To this end, in this study, we verified and confirmed that, in the Akita mouse model of diabetes, the thinning of the retinal nerve fiber layer/ganglion cell layer (the RNFL/GCL—the layer that contains the retinal ganglion cells) precedes the death of these same cells, suggesting that this dysfunction is a possible biomarker of retinal neurodegeneration. We then confirmed the validity of this assumption by starting a neuroprotective treatment (based on nerve growth factor eye drops) in concert with the first demonstration of RNFL/GCL thinning. In this way, it was possible not only to avoid the loss of retinal ganglion cells but also to prevent the subsequent development of the microvascular stage of diabetic retinopathy. In conclusion, in the case of diabetes, the thinning of the RNFL/GCL appears to be both a valid biomarker and a pharmacological target of diabetic retinopathy; it precedes the development of vascular dysfunctions and represents the ideal starting point for prevention.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Complications of Diabetes Unit, Diabetes Research Institute, IRCCS Ospedale San Raffaele, 20132 Milan, Italy.
- Centro per la Riferibilità Metrologica in Medicina di Laboratorio (CIRME), Dipartimento di Fisiopatologia Medico-Chirurgica e dei Trapianti, Università degli Studi di Milano, 20133 Milan, Italy.
- Istituto di Tecnologie Biomediche, Consiglio Nazionale delle Ricerche (ITB-CNR), 20054 Milan, Italy.
- Cornea and Ocular Surface Unit, IRCCS Ospedale San Raffaele, Vita-Salute San Raffaele University, 20132 Milan, Italy.
ORCID-Profile: Gianpaolo Zerbini, Silvia Galbiati
Förderung
- Dompé pharmaceuticals Spa, L'Aquila, Italy
- Italian Ministry of Health
Zitieren
APA
Zerbini, G., Maestroni, S., Viganò, I., Mosca, A., Paleari, R., Gabellini, D., Galbiati, S., & Rama, P. (2023). Progressive Thinning of Retinal Nerve Fiber Layer/Ganglion Cell Layer (RNFL/GCL) as Biomarker and Pharmacological Target of Diabetic Retinopathy. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms241612672
Vancouver
Zerbini G, Maestroni S, Viganò I, Mosca A, Paleari R, Gabellini D, et al. Progressive Thinning of Retinal Nerve Fiber Layer/Ganglion Cell Layer (RNFL/GCL) as Biomarker and Pharmacological Target of Diabetic Retinopathy. International Journal of Molecular Sciences. 2023. doi:10.3390/ijms241612672
BibTeX
@article{Zerbini2023,
author = {Zerbini, Gianpaolo and Maestroni, Silvia and Viganò, Ilaria and Mosca, Andrea and Paleari, Renata and Gabellini, Daniela and Galbiati, Silvia and Rama, Paolo},
title = {Progressive Thinning of Retinal Nerve Fiber Layer/Ganglion Cell Layer (RNFL/GCL) as Biomarker and Pharmacological Target of Diabetic Retinopathy},
journal = {International Journal of Molecular Sciences},
year = {2023},
doi = {10.3390/ijms241612672}
}
EUVIMED